# Purple Biotech LTD.: Form 20-F/A for the period ended Dec 31, 2020

- Company: [Purple Biotech LTD.](/companies/ppbt.md) (CIK 1614744)
- Form: 20-F/A
- Filed: 2021-03-16
- Accepted by EDGAR: Mar 16, 2021, 15:22 ET
- Period: 2020-12-31
- Accession: 0001213900-21-015664
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1614744/000121390021015664/f20f2020a1_purplebiotech.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1614744/000121390021015664/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2020-01-01 to 2020-12-31 | $1.0m | ifrs-full:Revenue |
| Operating income | 12 months, 2020-01-01 to 2020-12-31 | −$12.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Operating cash flow | 12 months, 2020-01-01 to 2020-12-31 | −$12.1m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2020-01-01 to 2020-12-31 | $156.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2020-12-31 | $11.2m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2020-12-31 | $59.3m | ifrs-full:CurrentAssets |
| Total assets | at 2020-12-31 | $83.8m | ifrs-full:Assets |
| Current liabilities | at 2020-12-31 | $3.1m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2020-12-31 | $79.4m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2020-12-31 | 17,210,574 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1614744/000121390021015664/f20f2020a1_purplebiotech.htm

Filed Mar 16, 2021.
Source: SEC EDGAR, the filing index for accession 0001213900-21-015664. Last ingested by Listed: Nov 12, 2026, 22:01 ET. No prices; not investment advice.
